#United States #Elk Grove Village #Orsini #Crinetics #PALSONIFY

Orsini and Crinetics: A New Era for Acromegaly Treatment

Orsini, a premier provider of pharmacy solutions for rare diseases, has now taken a significant stride by partnering with Crinetics Pharmaceuticals, Inc., to serve as the specialty pharmacy partner for their groundbreaking therapy, PALSONIFY™ (paltusotine). This agreement marks a pivotal moment in the treatment landscape for acromegaly, providing patients with an innovative oral therapy that has been granted FDA approval.

PALSONIFY™ stands out as the first once-daily oral treatment specifically developed for adults suffering from acromegaly. Traditionally, patients in this category faced significant challenges, especially those who had inadequate responses to surgical options or were not candidates for surgery at all. The introduction of PALSONIFY presents a promising alternative; it is a non-peptide, selectively-targeted somatostatin receptor type 2 (SST2) agonist, aimed at alleviating the symptoms associated with this rare endocrine disorder.

Acromegaly is primarily caused by a benign tumor on the pituitary gland that results in excessive secretion of growth hormone (GH). This condition often leads to noticeable physical alterations including enlarged hands, feet, and facial features, alongside a variety of serious health complications such as joint pain, metabolic disorders, cardiovascular issues, and respiratory problems. The untended progression of acromegaly can lead to severe health risks, including premature mortality.

Brandon Tom, CEO of Orsini, expressed the company’s commitment towards providing support and resources to the acromegaly community. He stated, “We’re honored to stand alongside Crinetics and the acromegaly community to provide access to PALSONIFY. Every step toward effective treatment matters.” This reflects Orsini's core mission of ensuring that patients receive compassionate and proactive care throughout their treatment journey.

As Orsini continues to lead in rare disease pharmacy solutions, PALSONIFY becomes the fifth therapy integrated into Orsini's Endocrinology Center of Excellence, which showcases the company’s extensive portfolio of specialized treatments. This comprehensive care approach highlights Orsini's dedication to delivering personalized support through pharmacy distribution, patient service coordination, clinical management, and home infusion services.

Orsini has received numerous accreditations from respected institutions, confirming its dedication to high standards in patient care. These accolades include accreditations from the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and NABP, alongside recognitions specific to rare disease pharmacy practices.

This partnership heralds a significant advancement in the treatment of acromegaly, benefitting not only the patients but also the healthcare providers involved in their care. By simplifying access to sophisticated therapies, Orsini and Crinetics are making strides toward a future where effective treatment solutions are within reach for those facing the challenges of acromegaly.

In conclusion, with the introduction of PALSONIFY and the partnership between Orsini and Crinetics, those affected by acromegaly can hope for improved quality of life through more effective and accessible treatment options. This collaboration exemplifies the vital role of dedicated pharmacy partners in the healthcare landscape, ensuring that no patient is left behind in their journey toward better health.